AVN-322

Last updated
AVN-322
AVN-322.svg
Names
IUPAC name
5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
Other names
List
  • 1194574-68-9
  • SB17475
  • 5-(Benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetraazatricyclo(7.4.0.0(2,6))trideca-1(9),3,5,7-tetraen-4-amine hydrochloride
  • starbld0039763
[1]
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
PubChem CID
UNII
  • hydrochloride:InChI=1S/C17H19N5O2S.ClH/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16;/h3-7,10H,8-9,11H2,1-2H3,(H,18,20);1H
    Key: HLQZXWFRTGIZIJ-UHFFFAOYSA-N
  • free base:InChI=1S/C17H19N5O2S/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16/h3-7,10H,8-9,11H2,1-2H3,(H,18,20)
    Key: OSHBEPOEBKFEEK-UHFFFAOYSA-N
  • hydrochloride:CNC1=NN2C3=C(CN(CC3)C)C=NC2=C1S(=O)(=O)C4=CC=CC=C4.Cl
  • free base:CNC1=NN2C3=C(CN(CC3)C)C=NC2=C1S(=O)(=O)C4=CC=CC=C4
Properties
C17H20ClN5O2S
Molar mass 393.891 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

AVN-322 is a 5-hydroxytryptamine subtype 6 receptor antagonist manufactured by Avineuro Pharmaceuticals Inc. that could potentially be used to combat Alzheimer's disease and schizophrenia. [2] [3] AVN-322 also reverses the negative effects of scopolamine and MK-80. [3]

The compound is a sister drug to AVN-101 and AVN-211, two similar compounds under trial for treating Alzheimer's. [3] Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010. [4] [5] The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commence Phase II trials later the same year. [5] The plan for further trials was discontinued in 2013. [6]

References

  1. ↑ National Center for Biotechnology Information. "Compound Summary for CID 135905417, B7DM6S48B2" PubChem. Accessed 12 March 2023.
  2. ↑ "AVN-322 | CAS#1194574-68-9 | CAS#1194574-33-8 | 5-HT6 Antagonist | MedKoo". www.medkoo.com. Retrieved 2023-03-12.
  3. 1 2 3 Andrews, Megan; Tousi, Babak; Sabbagh, Marwan N. (2018-06-01). "5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress". Neurology and Therapy. 7 (1): 51–58. doi:10.1007/s40120-018-0095-y. ISSN   2193-6536. PMC   5990506 . PMID   29728891. S2CID   19186491.
  4. ↑ "Avineuro Announces Beginning Of Phase I Clinical Studies Of AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease". BioSpace. Archived from the original on 12 Mar 2023. Retrieved 2023-03-12.
  5. 1 2 "Avineuro Reports Positive Phase I Clinical Trial Results On AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease". BioSpace. Archived from the original on 12 Mar 2023. Retrieved 2023-03-12.
  6. ↑ "Phase II trial of AVN 322 in patients with Alzheimer's disease. - AdisInsight". adisinsight.springer.com. Retrieved 2023-03-12.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.